基线疾病活动指数与用力肺活量预测系统性硬化症临床重要并发症及死亡
基于227例系统性硬化症(SSc)患者的前瞻性注册研究,基线改良EUSTAR疾病活动指数(mDAI)≥2.5定义的活跃疾病与复合终点(临床重要并发症或全因死亡)风险升高相关。多变量分析显示基线活跃疾病(HR 2.21,95%CI 1.06-4.59)和较低用力肺活量(HR 0.98每%,95%CI 0.96-0.99)独立预测不良结局。
要点
- 基线mDAI≥2.5的活跃疾病独立预测SSc临床重要并发症和死亡(HR 2.21)。
- 较低用力肺活量独立预测不良结局(HR 0.98每%,95%CI 0.96-0.99)。
- mDAI可作为超越间质性肺病进展的简单风险分层工具。
核心结论
- 基线mDAI和用力肺活量独立预测SSc疾病相关临床重要并发症和死亡。
- mDAI提供了超越间质性肺病进展的简单可行风险分层工具。
研究设计与样本
- 分析227例诊断为SSc并纳入前瞻性SSc注册研究的患者。
- 基线疾病活动用改良EUSTAR疾病活动指数(mDAI)评估,活跃疾病定义为mDAI≥2.5。
- 主要结局为基于修订CRISS第1步事件的疾病相关临床重要并发症复合终点或全因死亡。
- 使用Cox比例风险模型检验关联。
主要发现
- 基线时42例(18.5%)有活跃疾病。
- 中位随访38个月期间,45例(19.7%)患者发生主要结局。
- 活跃疾病与更高事件风险相关(log-rank P < 0.001)。
- 多变量分析中,基线活跃疾病(HR 2.21,95%CI 1.06-4.59)和较低用力肺活量(HR 0.98每%,95%CI 0.96-0.99)独立预测不良结局。
- 使用替代终点定义的敏感性分析结果一致。
关键数值与推荐
- 活跃疾病定义为mDAI≥2.5。
- 主要结局复合终点包括间质性肺病进展、毛细血管前肺动脉高压、硬皮病肾危象、心力衰竭、严重指端缺血或严重胃肠道功能障碍,或全因死亡。
临床怎么用
- 对SSc患者基线评估mDAI和用力肺活量有助于识别高危患者进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate whether the modified disease activity index (mDAI) predicts subsequent disease progression and organ damage in SSc. METHODS: We analysed 227 patients diagnosed with SSc who were enrolled in a prospective SSc registry. Baseline disease activity was assessed using the modified EUSTAR disease activity index (mDAI), with active disease being defined as an mDAI of ≥2.5. The primary outcome was a composite of disease-related clinically meaningful complications-based on revised CRISS step 1 events (interstitial lung disease progression, precapillary pulmonary hypertension, scleroderma renal crisis, heart failure, severe digital ischaemia, or severe gastrointestinal dysfunction)-or all-cause mortality. Associations were examined using Cox proportional hazards models. RESULTS: At baseline, 42 (18.5%) had active disease. During a median follow-up period of 38 months, 45 (19.7%) patients had experienced the primary outcome. Active disease was associated with a higher risk of events (log-rank P < 0.001). In multivariable analysis, baseline active disease [hazard ratio (HR) 2.21, 95% CI 1.06-4.59] and a lower forced vital capacity (HR 0.98 per %, 95% CI 0.96-0.99) independently predicted adverse outcomes. Results were consistent across sensitivity analyses using alternative end point definitions. CONCLUSION: Baseline mDAI and forced vital capacity independently predict disease-related clinically meaningful complications and mortality in SSc. The mDAI provides a simple, feasible tool for risk stratification beyond progression of interstitial lung disease.
引用
- Yen TH, Isomura Y, Suzuki M, et al. Baseline disease activity index and forced vital capacity predict clinically meaningful complications and mortality in systemic sclerosis. Rheumatology (Oxford). 2026. PMID: 42693930. doi:10.1093/rheumatology/keag481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。